Clinical Trial: Effect of Atorvastatin on Glycemic Control in Prediabetic Patients

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Effect of Atorvastatin on Glycemic Control in Prediabetic Patients

Brief Summary: The study was conducted to find out any possible effect of Atorvastatin on glycemic parameters in prediabetic patients.

Detailed Summary:

Diabetes is a growing public health problem throughout the world, threatening global health and economic prosperity. Currently, approximately 171 to 194 million people in the world have diabetes, the majority of the cases being Type II. This number is expected to increase to more than 330 million by the year 2025-a record doubling within a single generation. India with 62.2 million diabetic patients is fast becoming the diabetes capital of the world with possibility of the number of diabetic patients reaching the 80 million mark by 2030. Every sixth diabetic in the world is an Indian. China with 43.2 million patients comes second, followed by the US where 26.8 million people suffer from the disease.

This spectacular increase in the frequency of Type II diabetes is being paralleled by a similarly alarming increase in obesity, which is one of the major risk factors for Type II diabetes. Because of the close linkage of these two conditions, Ziv and Shafrir have suggested the term "diabesity" to describe this association. This dual epidemic which was largely ignored by the public health community until recently has come as a great surprise involving enormous economic burden as well as in terms of health. Disorders of glucose metabolism are associated with increased risk for cardiovascular disease (CVD) complications, including coronary, peripheral and cerebral arterial disease, that account for the majority of morbidity and mortality among patients with diabetes mellitus (DM).

Type II diabetes is commonly associated with dyslipidaemia, which represents a synergistic risk factor for cardiovascular disease. The National Cholesterol Education Program Adult Treatment Panel III (ATP III) listed diabetes as a coronary heart disease (CHD) risk equivalent for setting therapeutic goals for LDL cholesterol. A goal for LDL chol
Sponsor: Shri Ramachandra Bhanj Medical College

Current Primary Outcome: Change in Glycosylated Hemoglobin (HbA1c) from baseline [ Time Frame: At baseline and at 6 monhts, 12 months and 18 months follow up ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Change in Fasting blood sugar from baseline [ Time Frame: At baseline and at 6 monhts, 12 months and 18 months follow up ]
  • Change in Post prandial blood sugar from baseline [ Time Frame: At baseline and at 6 monhts, 12 months and 18 months follow up ]
  • Lipid profile [ Time Frame: At baseline ]


Original Secondary Outcome: Same as current

Information By: Shri Ramachandra Bhanj Medical College

Dates:
Date Received: June 4, 2015
Date Started: July 2011
Date Completion:
Last Updated: August 14, 2015
Last Verified: August 2015